PRESS RELEASE published on 10/10/2025 at 18:17, 7 months 11 days ago Rapport financier semestriel 2025
BRIEF published on 08/04/2025 at 08:03, 9 months 17 days ago AB Science finalise un placement privé de 2,55 millions d'euros Actionnaires Placement Privé Développement Clinique AB Science 2,55 Millions D'euros
BRIEF published on 08/04/2025 at 08:03, 9 months 17 days ago AB Science Completes EUR 2.55 Million Private Placement Private Placement Shareholders Clinical Development AB Science EUR 2.55 Million
PRESS RELEASE published on 08/04/2025 at 07:58, 9 months 17 days ago AB Science annonce le succès d’un placement privé d’environ 2,55 millions d’euros AB Science annonce le succès d'un placement privé de 2,55 millions d'euros pour financer le développement clinique du programme AB8939 Capital Financement Placement Privé AB Science Programme AB8939
PRESS RELEASE published on 08/04/2025 at 07:58, 9 months 17 days ago AB Science announces the successful completion of a 2.55 million euros private placement AB Science successfully completes EUR 2.55 million private placement to fund clinical development. New shares issued with warrants attached Private Placement Shareholders Clinical Development AB Science EUR 2.55 Million
BRIEF published on 07/30/2025 at 07:50, 9 months 22 days ago AB Science Advances in AML Study With New European Approvals Regulatory Approval Market Potential AB8939 Venetoclax AML Study
BRIEF published on 07/30/2025 at 07:50, 9 months 22 days ago AB Science progresse dans l'étude sur la LAM grâce à de nouvelles autorisations européennes Approbation Réglementaire Potentiel Du Marché AB8939 Venetoclax Étude Sur La LAM
PRESS RELEASE published on 07/30/2025 at 07:45, 9 months 22 days ago AB Science a reçu l’approbation règlementaire de pays européens pour initier la troisième étape de la phase I/II visant à combiner sa molécule AB8939 avec le venetoclax dans le traitement de la LMA AB Science reçoit l'approbation réglementaire pour la phase I/II de l'étude combinant AB8939 et venetoclax dans le traitement de la leucémie myéloïde aiguë. Étude en cours en Europe AB Science AB8939 Leucémie Myéloïde Aiguë Venetoclax Phase I/II
PRESS RELEASE published on 07/30/2025 at 07:45, 9 months 22 days ago AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining AB8939 with venetoclax for treatment of acute myeloid leukemia Regulatory Approval AB Science AB8939 Venetoclax Phase I/II Study
BRIEF published on 07/24/2025 at 08:01, 9 months 28 days ago AB Science Gains Approval for Phase 3 ALS Masitinib Study Across Europe Phase 3 Trial ALS AB Science Masitinib European Approval
Published on 05/21/2026 at 15:00, 3 hours 43 minutes ago Karbon-X Expands Global Energy Attribute Certificate Market Capabilities Amid Growing Renewable Procurement Demand
Published on 05/21/2026 at 14:30, 4 hours 13 minutes ago Rio Grande Resources Advances District-Scale Gold-Silver Target Definition at its Winston Project Through Structural Mapping of Multiple Vein Corridor Systems
Published on 05/21/2026 at 14:00, 4 hours 43 minutes ago Nextech3d.ai to Showcase AI Event Operating System and Krafty Labs Marketplace at Leading EMRG Media Event in New York
Published on 05/21/2026 at 14:00, 4 hours 43 minutes ago Jade Leader Reviews Its Available Critical Minerals Assets
Published on 05/21/2026 at 14:00, 4 hours 43 minutes ago Horizon Aircraft Advances Dual-Use Certification Path Through Cert Center Canada Partnership
Published on 05/21/2026 at 18:26, 16 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/21/2026 at 18:00, 42 minutes ago E-PANGO: Mise en place d’un financement obligataire d’un montant nominal maximum de 4 M€
Published on 05/21/2026 at 17:56, 46 minutes ago Annual General Meeting 2026: Adval Tech shareholders approve all proposals
Published on 05/21/2026 at 17:45, 57 minutes ago Linedata Services: Assemblée Générale Mixte Modalités de mise à disposition des documents préparatoires
Published on 05/21/2026 at 17:43, 59 minutes ago Vonovia SE: AGM approves €1.25 dividend per share and appoints Dr Anne-Marie Großmann-Minkwitz to the Supervisory Board
Published on 05/21/2026 at 17:45, 58 minutes ago CEGEDIM: DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 05/21/2026 at 16:35, 2 hours 7 minutes ago 260521 BENETEAU Déclaration du nombre d'actions et de droits de vote au 30-04-2026